WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) released its financial results for the first quarter of 2025, alongside updates on its expanding immuno-inflammatory (I&I) pipeline and leadership changes. The company remains focused on achieving key clinical milestones while maintaining financial discipline.
Aclaris reported a net loss of $15.1 million for Q1 2025, an improvement from the $16.9 million loss reported in the same period last year. Revenue for the quarter totaled $1.5 million, slightly down from $2.4 million in Q1 2024. The company ended the quarter with $190.5 million in cash, cash equivalents, and marketable securities, which it anticipates will fund operations through the first half of 2028.
CEO Dr. Neal Walker noted this as a “transformative multi-year period” for Aclaris. “We remain committed to efficient clinical execution while advancing our pipeline of innovative T cell and monoclonal antibody therapies,” he stated.
Key pipeline developments include significant progress with bosakitug (ATI-045), the company’s anti-TSLP monoclonal antibody. Following successful Phase 2a trial data for atopic dermatitis (AD), Aclaris plans to begin a placebo-controlled Phase 2 trial in Q2 2025. Additionally, results from the company’s Chinese partner, CTTQ, have demonstrated the enhanced potency of bosakitug in respiratory conditions, including asthma and CRSwNP. While Aclaris intends to focus on AD, global development in respiratory indications will hinge on securing partnerships.
Other pipeline highlights include the completion of dosing in a Phase 2a trial for ATI-2138, an oral ITK/JAK3 inhibitor for AD, with results expected in June 2025. The U.S. FDA recently cleared an IND for bispecific antibody ATI-052, with Phase 1 trials set to start in Q2 2025.
On the corporate front, Aclaris appointed Dr. Jesse W. Hall as Chief Medical Officer. Dr. Hall brings extensive experience from early development to global regulatory filings and commercial launches.
With a robust pipeline, disciplined financial management, and strategic partnerships on the horizon, Aclaris appears poised to advance its portfolio of therapies targeting a wide range of immuno-inflammatory conditions.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.